Sana Biotechnology
Clinical trials sponsored by Sana Biotechnology, explained in plain language.
-
New 'Off-the-Shelf' cell therapy takes on Hard-to-Treat blood cancers
Disease control OngoingThis early-stage study tests a new treatment called SC291 for people with certain types of blood cancer (non-Hodgkin lymphoma or chronic lymphocytic leukemia) that have come back or not responded to other treatments. SC291 is a type of immune cell therapy made from donor cells, d…
Phase: PHASE1 • Sponsor: Sana Biotechnology • Aim: Disease control
Last updated Jun 15, 2026 19:05 UTC
-
New 'Off-the-Shelf' cell therapy targets Hard-to-Treat lymphoma
Disease control OngoingThis early-phase study tests a new treatment called SC262 for people with Non-Hodgkin's lymphoma that has come back or not responded to other therapies. SC262 uses donor immune cells engineered to find and attack cancer cells. The main goal is to check safety and find the right d…
Phase: PHASE1 • Sponsor: Sana Biotechnology • Aim: Disease control
Last updated Jun 15, 2026 19:05 UTC
-
Engineered immune cells take on lupus and vasculitis in early trial
Disease control OngoingThis early-phase study tests a new treatment called SC291 for people with severe lupus or vasculitis that hasn't responded to standard therapies. SC291 uses donor immune cells engineered to target and destroy faulty immune cells driving the disease. The main goal is to check safe…
Phase: PHASE1 • Sponsor: Sana Biotechnology • Aim: Disease control
Last updated Jun 15, 2026 18:54 UTC